Predict your next investment

Beacon Biomedical company logo
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
beaconbiomedical.com

See what CB Insights has to offer

Founded Year

2014

Stage

Seed - II | Alive

Total Raised

$1.5M

Last Raised

$520K | 4 yrs ago

About Beacon Biomedical

Beacon Biomedical is a medical diagnostic development and a Centers of Medicare and Medicaid Services (CMS) CLIA accredited laboratory services company providing easy, accurate, and affordable blood tests for earlier cancer detection. Its laboratory-developed test (LDT) solutions are developed for healthcare practitioners and individuals alike and are intended to be used as screening tests for the presence of undiagnosed cancer. They are specifically designed for those who are unwilling or unable to participate in cancer screening using current procedures and tests. The company's focus is on providing blood-based cancer screening alternatives in order to improve screening participation and earlier detection of these devastating diseases.

Beacon Biomedical Headquarter Location

275 N. GateWay Drive Suite 149

Phoenix, Arizona, 85034,

United States

480-757-9037

Latest Beacon Biomedical News

University of North Dakota Centers for Family Medicine Pursuing Research Study on Blood-based Colorectal Cancer Screening

Jun 1, 2021

Phoenix, Arizona, June 1, 2021 – The University of North Dakota (UND) Center for Family Medicine (CFM) in Bismarck is partnering with Beacon Biomedical Inc. to study a new blood-based colorectal cancer (CRC) screening test, called BeScreened-CRC, for North Dakota patients. Developed by Beacon Biomedical, this federal Clinical Laboratory Improvement Amendments (CLIA) test for CRC screening has been on the market for a short time. While its performance has been demonstrated in case-control studies, its effectiveness has yet to be compared directly to that of more traditional colorectal cancer screenings such as colonoscopy and fecal-based testing. Dr. Jeff Hostetter, Director of the UND CFM in Bismarck “We need to get more people screened for colon cancer, period,” said Dr. Jeff Hostetter, Director of the UND CFM in Bismarck, explaining how many patients avoid colonoscopies for a variety of reasons. “Ultimately, we want everybody who is eligible to be screened for colon cancer to get a colonoscopy. However, not everyone who needs one will agree to undergo the procedure. But if the results of this study are positive, they might not have to.” Despite being one of the most preventable forms of cancer, colorectal cancer remains the nation’s second deadliest cancer, claiming more than 53,200 lives in 2020. Among those 53,000 deaths, as many as 30,000 people – more than 56 percent of deaths – could have been prevented with early detection. Unfortunately, many people still avoid screening because they find existing recommended procedures unpleasant, inconvenient, and/or unacceptable, even when they understand the dangers of colorectal cancer. This is where a UND Institutional Review Board (IRB)-approved study on a CRC blood test comes in. Donald F. Weber, CEO of Beacon Biomedical “This is another tool in the toolbox [for physicians],” added Donald F. Weber, CEO of Beacon Biomedical, explaining how the noncompliance or screening “reluctance” rate for patients who have been advised by a physician to get a colonoscopy is still too high in the U.S. “We know there’s a huge colon cancer disparity in the African American and American Indian communities from the higher incidence and mortality rates we see. One possible reason for this disparity is the screening participation rates in these populations.” According to Weber, recent data shows almost a 40% screening reluctance rate for African Americans and a 64% rate for American Indians. Furthermore, patient surveys indicate that 83% of persons who refuse a colonoscopy or fecal-based test would accept an effective blood test for colorectal cancer screening if it were available. “If we can make colorectal cancer screening something physicians can do in-clinic, we are likely to see a higher rate of screening, which can really make a positive impact on healthcare outcomes,” he said. Colonoscopy is still the gold standard for colorectal screening, said Hostetter, who makes the procedure his first recommendation. However, given the current level of screening hesitancy he sees, Hostetter was happy to participate in a clinical study on a CRC blood test. Marc Basson, Senior Associate Dean of Medicine and Research at the UND School of Medicine & Health Sciences As Hostetter explained, when patients come into the clinic and are eligible for colon cancer screening, the CFM offers them one of the more traditional screenings, which is standard colorectal cancer protocol based on each patient’s individual risk factors. Now, through this study, Hostetter’s team will also ask patients who are getting a colonoscopy or taking a fecal-based test if they want the blood test as well. For those who do, the BeScreened-CRC test will be provided and results compared with their colonoscopy or fecal-based test. “If this test is proven effective at detecting cancer in the clinical setting, this would be a valuable adjunct to the primary care doc’s repertoire,” added Dr. Marc Basson, Senior Associate Dean of Medicine and Research at the UND School of Medicine & Health Sciences. “That is what this study is all about.” “The idea of a blood test for colon cancer screening has been the holy grail for years,” Hostetter said. “If we can show that the blood test is a reliable screening tool for colon cancer, we would be able to dramatically improve screening compliance rates, which in turn would lead to earlier cancer detection and more lives saved from this devastating disease.” About University of North Dakota (UND) Center for Family Medicine Staffed by a team of board-certified faculty physicians and skilled resident physicians, UND Center for Family Medicine attracts top-notch medical school graduates who complete their residency education as well-trained, caring family doctors. UND Center for Family Medicine has supplied over 85 percent of board-certified family physicians to the Bismarck/Mandan area, providing a continual stream of new doctors to ensure that your health needs are taken care of now and in the future. For more information visit,  http://www.cfmbismarck.und.edu/about/ About University of North Dakota (UND) School of Medicine & Health Sciences Founded in 1905, the UND School of Medicine & Health Sciences (SMHS) is the only medical school in North Dakota. Today, two out of every three family physicians in the state received their medical degree from UND. SMHS researchers conduct over $30 million worth of research annually. The School also offers programs in physical therapy, occupational therapy, public health, medical laboratory science, physician assistant studies, and athletic training. It also offers master and doctoral graduate programs in Clinical & Translational Science and Biomedical Sciences. For more information visit, https://med.und.edu/about/index.html About Beacon Biomedical Inc. Beacon Biomedical Inc. is a CLIA accredited proteomic diagnostics laboratory focused on developing and commercializing laboratory developed tests and point-of-care CLIA waived tests for earlier cancer detection. The company’s lead product, BeScreened™-CRC, is a blood-based test for the early detection of colorectal cancer. Beacon’s product development pipeline initiatives include early detection assays for breast, lung, and prostate cancers. For more information visit, www.beaconbiomedical.com .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Beacon Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Beacon Biomedical is included in 5 Expert Collections, including Cancer Liquid Biopsies.

C

Cancer Liquid Biopsies

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

7,867 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,390 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Beacon Biomedical Patents

Beacon Biomedical has filed 10 patents.

The 3 most popular patent topics include:

  • Orthopedic surgical procedures
  • Skeletal system
  • Bone fractures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/14/2015

9/22/2020

Orthopedic surgical procedures, Joints, Pelvis, Ligaments of the torso, Bones of the vertebral column

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/14/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/22/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Orthopedic surgical procedures, Joints, Pelvis, Ligaments of the torso, Bones of the vertebral column

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Beacon Biomedical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Beacon Biomedical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.